Alisha Stein

616 total citations · 1 hit paper
14 papers, 446 citations indexed

About

Alisha Stein is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alisha Stein has authored 14 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alisha Stein's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (4 papers) and Cancer Genomics and Diagnostics (3 papers). Alisha Stein is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (4 papers) and Cancer Genomics and Diagnostics (3 papers). Alisha Stein collaborates with scholars based in United States, Russia and India. Alisha Stein's co-authors include Funda Meric‐Bernstam, Bongin Yoo, John D. Hainsworth, Herbert I. Hurwitz, Howard A. Burris, Razelle Kurzrock, Ron Bose, Mary Beattie, Charles Swanton and Christopher J. Sweeney and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Therapeutics and Clinical journal of oncology nursing.

In The Last Decade

Alisha Stein

14 papers receiving 432 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

2018 357 citations John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology profile →

Peers

Alisha Stein

ONCOL

PRM

CR

PFM

SURGE

Mei-Ching Liu Taiwan

Hagen Kennecke Canada

Amin Haiderali United States

Cristina Sonetto Italy

Pedro Nazareth Aguiar Brazil

Melina Flanagan United States

V. Papadimitrakopoulou United States

Hans M. Westgeest Netherlands

Kian Fong Foo Singapore

Franco Testore Italy

Mei-Ching Liu Taiwan

Alisha Stein

323 ×1.0

ONCOL

127 ×0.8

PRM

176 ×1.2

CR

82 ×0.9

PFM

69 ×0.9

SURGE

Citations per year, relative to Alisha Stein Alisha Stein (= 1×) peers Mei-Ching Liu

Countries citing papers authored by Alisha Stein

Since Specialization

Citations

This map shows the geographic impact of Alisha Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alisha Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alisha Stein more than expected).

Fields of papers citing papers by Alisha Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alisha Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alisha Stein. The network helps show where Alisha Stein may publish in the future.

Co-authorship network of co-authors of Alisha Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Alisha Stein. A scholar is included among the top collaborators of Alisha Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alisha Stein. Alisha Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Hopson, Sari, Andrew Renda, Aparna R. Parikh, et al.. (2019). Using the Healthy Days Measure to Assess Factors Associated with Poor Health-Related Quality of Life for Patients with Metastatic Breast, Lung, or Colorectal Cancer Enrolled in a Medicare Advantage Health Plan. Population Health Management. 22(5). 440–448. 7 indexed citations

2.

Satram‐Hoang, Sacha, et al.. (2019). Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data. Journal of Cancer Therapy. 10(2). 117–133. 1 indexed citations

3.

Hainsworth, John D., Funda Meric‐Bernstam, Charles Swanton, et al.. (2018). Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology. 36(6). 536–542. 357 indexed citations breakdown →

4.

Michael, Todd P., Andrew Renda, Sari Hopson, et al.. (2018). The relationship between comorbidity medication adherence and health related quality of life among patients with cancer. Journal of Patient-Reported Outcomes. 2(1). 29–29. 21 indexed citations

5.

Lin, Nancy U., Alisha Stein, Alan Nicholas, et al.. (2017). Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC).. Journal of Clinical Oncology. 35(15_suppl). 2074–2074. 11 indexed citations

6.

Satram‐Hoang, Sacha, et al.. (2017). Which patient characteristics drive treatment decisions in elderly patients with early stage hormone receptor–positive breast cancer?. Journal of Clinical Oncology. 35(15_suppl). 538–538. 2 indexed citations

7.

Sussman, Matthew, Jeffrey Yu, Carolina Reyes, et al.. (2017). How are quality of life and work productivity associated with living longer with HER2+ metastatic breast cancer?. Journal of Clinical Oncology. 35(5_suppl). 215–215. 2 indexed citations

8.

Hainsworth, John D., Funda Meric‐Bernstam, Charles Swanton, et al.. (2016). Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.. Journal of Clinical Oncology. 34(18_suppl). LBA11511–LBA11511. 6 indexed citations

9.

Hainsworth, John D., Funda Meric‐Bernstam, Charles Swanton, et al.. (2016). Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.. Journal of Clinical Oncology. 34(15_suppl). LBA11511–LBA11511. 2 indexed citations

10.

Hopson, Sari, et al.. (2016). Is there a relationship between self-reported healthy days and comorbidity medication adherence among oncology patients?. Journal of Clinical Oncology. 34(7_suppl). 189–189. 2 indexed citations

11.

Franco, Sandra, Grace Wang, Neil Abramson, et al.. (2011). A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer. Community Oncology. 8(5). 209–215. 1 indexed citations

12.

Stein, Alisha. (2010). Ixabepilone. Clinical journal of oncology nursing. 14(1). 65–71. 3 indexed citations

13.

Mahtani, Reshma, Alisha Stein, & Charles L. Vogel. (2009). High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review. Clinical Therapeutics. 31. 2371–2378. 20 indexed citations

14.

Maxwell, Cathy & Alisha Stein. (2006). Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: from paper to clinical practice. Community Oncology. 3(8). 530–536. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact